



UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE 6 MONTHS PERIOD ENDED 30 June 2021

Prepared in accordance with the requirements of the
international financial reporting standards
as adopted by the European Union

Olaine, 2021



FORWARD
WITH THE
NEW STRATEGY
2020-2025

Olainfarm Group

JSC Olainfarm is one of the leading manufacturers in the chemical and pharmaceutical sector of the Baltic States with more than 45 years of experience. Portfolio contains over 60 FDFs, 25 APIs and more than 20 Intermediates.

The key areas of specialization in FDFs include neurology, cardiology, infectiology and allergology. JSC Olainfarm has a long-standing technological and know-how advantage in adamantane, quinuclidine and nitrofurans chemistry.

JSC Olainfarm is licensed manufacturer of chemical and pharmaceutical products, endowed with modern technologies and certified in accordance with the requirements of the EU and Russia' Good Manufacturing Practice, ISO 14001:2015 Environmental Management System, in certain categories - in accordance with the U.S. standards (FDA), Australian standards (TGA), Japan standards (PMDA).



CORPORATE MISSION:

We improve customers' lives and create value to our organization by providing sustainable healthcare products and services leveraging on our manufacturing and commercial expertise.

VISION:

By the year 2025 we are the TOP 10 CEE manufacturing company sustainably delivering healthcare products and services in specific therapeutic areas in CEE, CIS and beyond.

Corporate information

	Joint stock company OLAINFARM
Information on Parent company of the Group	Manufacturing and distribution of chemical and pharmaceutical products Unified registration number: 40003007246 Registration: Riga, 10 June 1991 (re-registered on 27 March 1997) Address: Rūpnīcu iela 5, Olaine, Latvia, LV-2114
Largest subsidiaries (100%)	SIA Latvijas Aptieka – pharmacy chain SIA Silvanols – Latvian food supplement company SIA Tonus Elast – producer of elastic and compression medical products
Financial year	1 January – 31 December 2021
Interim reporting period	1 January – 30 June 2021

Corporate Governance

SUPERVISORY COUNCIL

(Elected for the term from 17 June 2021 to 16 June 2026)

Juris Bundulis Chairman of the Supervisory Council	Positions held in other companies: AS Rīgas Farmaceutiskā Fabrika, Member of the supervisory council (until 22 June 2021) AS RPH Marketing Latvia, Member of the supervisory council (until 22 June 2021) AS Sentor Farm Aptiekas, Member of the supervisory council (until 22 June 2021) AS Recipe Plus, Member of the supervisory council (until 22 June 2021) AS RPH Business Suport, Member of the supervisory council (until 22 June 2021) AS Repharm, Member of the supervisory council (until 22 June 2021)
Irina Maligina Deputy chairman of the Supervisory Council	Shareholding in other companies: none Positions held in other companies: SIA OLFIM M, Chairman of the board OÜ OLFIM (Estonia), Board member Shareholding in other companies: SIA OLFIM M (100 %) OÜ OLFIM (100 %) SIA OLMAFARM (as co-heir of 1/3 from 100 %) SIA OLALEX (as co-heir of 1/3 from 50 %)
Sandis Petrovičs Deputy chairman of the Supervisory Council	Positions held in other companies: SIA TGS Baltic zvērīnātu advokātu birojs, Board member (from 14 July 2021) SIA EZERKRASTA ZEME, Board member Shareholding in other companies: SIA TGS Baltic zvērīnātu advokātu birojs (14.29 %)
Andrejs Leibovičs Member of the Supervisory Council	Positions held in other companies: AS Rīgas Farmaceutiskā Fabrika, Chairman of the supervisory council AS RPH Marketing Latvia, Chairman of the supervisory council AS Sentor Farm Aptiekas, Chairman of the supervisory council AS Recipe Plus, Chairman of the supervisory council AS RPH Business Suport, Chairman of the supervisory council AS Repharm, Chairman of the supervisory council AS BA Trust, Chairman of the board AS AB CITY, Member of the supervisory council Shareholding in other companies: Limited Partnership ZGI Real Estate T15 (limited partner)
Pēteris Rubenis Member of the Supervisory Council	Positions held in other companies: SIA OLMAFARM, Board member SIA LATELEKTRO, Board member SIA REML RŪPNĪCA, Board member SIA Tērbatas 4-11, Board member SIA Pētera Rubeņa juridiskais birojs, Board member SIA HEIDELBERGA, Board member SIA Lielkalns, Board member Shareholding in other companies: SIA Tērbatas 4-11 (100 %) SIA Pētera Rubeņa juridiskais birojs (100 %) SIA Lielkalns (100 %)

CHANGES IN THE SUPERVISORY COUNCIL

Gundars Bērziņš Chairman of the Supervisory Council until 17 June 2021	Positions held in other companies (as of 17 June 2021): none Shareholding in other companies (as of 17 June 2021): SIA MeadowMe (99.96 %)
Jānis Buks Deputy chairman of the Supervisory Council until 17 June 2021	Positions held in other companies (as of 17 June 2021): SIA JV Holdings, Board member AS Spring Holding, Board member SIA LNK Asset Management AIFP, Chairman of the board AS Latvijas balzams, Member of the supervisory council SIA IJ birojs, Board member (from 1 April 2021) Shareholding in other companies (as of 17 June 2021): SIA JV Holdings (50 %) SIA IJ birojs (100 % from 23 March 2021)
Kārlis Krastiņš Deputy chairman of the Supervisory Council until 17 June 2021	Positions held in other companies (as of 17 June 2021): SIA Xiexie, Chairman of the board SIA Prudentia Advisers, Chairman of the board AS Prudentia, Chairman of the board SIA Prudentia Private Equity Partners, Board member Shareholding in other companies (as of 17 June 2021): SIA Xiexie (100 %) SIA Prudentia Advisers (44.49 %) AS Prudentia (18.63 %) SIA Prudentia Private Equity Partners (100 %)
Haralds Velmers Member of the Supervisory Council until 17 June 2021	Positions held in other companies (as of 17 June 2021): SIA VH Invest, Board member S.R.O. VH Latvia Invest, Board member Shareholding in other companies (as of 17 June 2021): SIA Compor (7.73 %) SIA Nami un būves (40 %) SIA VH Invest (100 %)
Andrejs Saveļjevs Member of the Supervisory Council until 17 June 2021	Positions held in other companies (as of 17 June 2021): SIA B28, Board member Shareholding in other companies (as of 17 June 2021): SIA RAAP (45 %) SIA Dzīvokļu īpašumi (16.67 %)

AUDIT COMMITTEE

(Elected for the term from 17 June 2021 to 16 June 2023)

Members	Viesturs Gurtlavs - Chairman of the Audit Committee Sandis Petrovičs - Member of the Audit Committee, Deputy chairman of the Supervisory Council Arnis Gulbis - Member of the Audit Committee
---------	--

(Elected for the term from 1 April 2019 to 31 March 2021)

Members	Agris Auce - Chairman of the Audit Committee Kārlis Krastiņš - Member of the Audit Committee, Deputy chairman of the Supervisory Council Viesturs Gurtlavs - Member of the Audit Committee
---------	---

REMUNERATION COMMITTEE

(Elected for the term from 17 June 2021 to 16 June 2026)

Members	Juris Bundulis - Chairman of the Remuneration committee, Chairman of the Supervisory Council
	Sandis Petrovičs - Member of the Remuneration Committee, Deputy chairman of the Supervisory Council
	Pēteris Rubenis - Member of the Remuneration Committee, Member of the Supervisory Council
	Viesturs Gurtlavs - Member of the Remuneration Committee, Chairman of the Audit Committee
	Evita Osīte - Member of the Remuneration Committee

(Elected for the term from 12 November 2020 to 17 June 2021)

Members	Gundars Bērziņš - Chairman of the Remuneration committee, Chairman of the Supervisory Council
	Agris Auce - Member of the Remuneration Committee
	Jānis Buks - Member of the Remuneration Committee, Deputy chairman of the Supervisory Council
	Haralds Velmers - Member of the Remuneration Committee, Member of the Supervisory Council
	Evita Osīte - Member of the Remuneration Committee

MANAGEMENT BOARD

The Supervisory Council of the company elects the Management Board of JSC Olainfarm for five years. When selecting the members of the Management Board, the Supervisory Council assesses the experience of candidates in team management, in particular – in the area of responsibility of a candidate and in the pharmaceutical sector in general.

**Jānis Buks**

Chairman of the Management Board
Since 30 July 2021

**Elena Bushberg**

Board member
Since 5 December 2019

**Signe Baldere-Sildedze**

Board member
Since 4 April 2019

**Jānis Leimanis**

Board member
Since 17 June 2021

**Raimonds Terentjevs**

Board member
Since 28 December 2017

CHANGES IN THE MANAGEMENT BOARD

Milana Beļeviča	Board member until 29 April 2021
Zane Kotāne	Board member until 19 May 2021
Jeroen Hidde Weites	Chairman of the Management Board until 8 June 2021

Shares and Shareholders

Share capital of JSC Olainfarm consists of 14 085 078 ordinary shares, which are booked in Nasdaq CSD depository and are listed on the Nasdaq Riga Baltic Main List. All shares have equal rights and each share has one voting right respectively. In the reporting period the total number of shares has not changed. The company does not own any treasury shares.

ISIN	LV0000100501
Exchange Code	OLF1R
List	Riga, Baltic Official List
Nominal Value	1.40 EUR

Total shares	14 085 078
Shares on public quotation	14 085 078

Source: Nasdaq Riga

TRADING


During six months of 2021 JSC Olainfarm average share price was EUR 7.46 per 1 share and traded in a range of EUR 7.02 to 9.20 per share. During this period 6 170 transactions with 529 573 shares with total value of EUR 4 067 222.70 took place.




During the last 12 months until end of the reporting period OMX Riga gross index increased by 15.98 % and the share price of JSC Olainfarm increased by 22.80 %. The next chart shows share price of JSC Olainfarm on the Nasdaq Riga stock exchange relative to OMX Riga gross index over the last 12 months until the end of the reporting period.



JSC Olainfarm share price changes for the past three years until the end of the reporting period



During the second quarter of 2021, more than 335 thousand shares of JSC Olainfarm, with a total value of EUR 2.6 million, were traded on Nasdaq Riga. Compared to the same period in 2020, the number of traded shares was higher by 11 %, while traded value was higher by 25 %.



RESULTS OF SHARE TRADING

	2021 (6 months)	2020 (6 months)	2019 (6 months)
Share price (EUR):			
The first	7.24	7.30	6.70
Highest	9.20	7.66	7.25
Lowest	7.02	5.36	5.44
Average	7.46	6.88	6.60
The last	8.94	7.28	6.94
Changes (between the first and the last price)	2.18	2.30	1.81
Number of transactions	6 170	5 750	3 500
Shares traded	529 573	748 447	888 025
Turnover (mil. EUR)	4.07	5.07	5.59
Capitalization (mil. EUR)	125.92	102.54	97.75

SHAREHOLDER STRUCTURE AND LARGEST SHAREHOLDERS

As of 30 June 2021 JSC Olainfarm had 1 854 shareholders, incl. nominal account holders. Investors from the Baltic States comprised 97 % of total number of shareholders, the most represented are Latvian residents, Estonian and Lithuanian investors hold the second and the third place respectively.

THE LARGEST SHAREHOLDERS, % OF TOTAL SHARES



JSC OLAINFARM SHARES OWNED BY THE GOVERNANCE STRUCTURE (30 JUNE 2021)

Management Board		
Board member	Elena Bushberg	None
Board member	Signe Baldere-Sildedze	directly: 297 manages 1 097 026 shares of JSC Olainfarm as a natural guardian of the minor shareholder Anna Emīlija Maligina
Board member	Jānis Leimanis	directly: 0 indirectly : 10 521 (through SIA JL Index)
Board member	Raimonds Terentjevs	None
Supervisory Council		
Chairman of the Supervisory Council	Juris Bundulis	None
Deputy Chairman the Supervisory Council	Irina Maligina	directly: 0 indirectly : 1 097 051 (through OÜ OLFIM)
Deputy Chairman the Supervisory Council	Sandis Petrovičs	None
Member of the Supervisory Council	Andrejs Leibovičs	None
Member of the Supervisory Council	Pēteris Rubenis	20

Management Report

OPERATING ENVIRONMENT

In the first half of 2021, the Group's business environment was still affected by the Covid-19 pandemic: restrictions introduced, shrinking revenues, falling demand. Some business segments have performed to successfully meet new demands, others have faced challenges, and still others have been relatively less impacted by the pandemic. Negative development of a macroeconomic nature impacted sales results in important sales markets. The group met these challenges through diversifying business, providing comprehensive monitoring and assessment of market developments.

In the reporting period, the group's sales volume amounted to 66 671 thousand EUR. Cumulative six months sales ratio is at last year level, however the last year sales include EUR 9 million unexpected deliveries to Russia in June 2020 in anticipation of serialization.

The Covid pandemic led to depreciation of local currency in Russia, Belorussia, Central Asia and Caucasus and inflation for medicine prices in those countries where prices are not controlled in 2020.

In contrast to declining pharmaceutical markets Olainfarm medicines continued growing and gaining market share in the first half of 2021 with remarkably good performance in Russia, Ukraine, Uzbekistan, Latvia, Kazakhstan and Georgia. One of the reasons for growth is successful



implementation of the new business model in Ukraine, Russia, and Kazakhstan and professional and well-established marketing team in Latvia. Despite weak OTC market results in the first six months of 2021, Olainfarm products have shown strong demand due to product mix, brand recognition and renewed marketing strategy.

One of the most important markets is Russia. Group subsidiary in Russia is actively operating, proceeding with established robust digital communication channels, created patient support programs for anxiety discussions, and developed educational platform for healthcare professionals.

Group's net profit for the reporting period is 7 668 thousand EUR, which is a decrease of 2 349 thousand EUR or 23% against the previous year' figure. Raise in sales in Russia and Ukraine led to increase in selling expenses in these markets, other operating costs include additional provisions for bad-debts.

JSC Olainfarm is using Financial Risk Management Policy to mitigate the risks related to exchange rate fluctuations.

Covid-19 pandemic restrictions and economic consequences significantly influenced the possibilities of the Group to realize planned investments.

THE IMPACT OF COVID-19

During the reporting period, the Group continued to secure the precautionary measures in the production premises, the administration and sales structures, ensured organizational and hygiene requirements, the possibility of carrying out work duties remotely, providing informational and other activities.

Under the national vaccination programme JSC Olainfarm provided vaccination for the employees in order to take care of health and safety during the pandemic. SIA "Klīnika DiaMed" and SIA "Olainmed" have engaged in vaccination of Latvian residents against Covid-19, setting up vaccination points in Riga and Olaine.

Several of the Group companies used the opportunity provided by the Latvian State to receive financial support for Covid-19 crisis mitigation and the motivation of medical personnel. In total, in the first 6 months of 2021, the Group companies have received Latvian State financial support amounting to EUR 183 thousand.

Pandemic penetration left impact on Group subsidiaries' results. A significant reduction in demand in retail sales was caused by legislative restrictions on the organizational procedures for physical visits and trading areas in ambulatory institutions, shopping centers.

Significant impact comes from the drop in demand for the leading product category in health-enhancing – products for treatment of cold symptoms. Cold and Cough markets are declining across all countries driven by COVID-19 constraints and low acute respiratory viral infection (ARVI) incidence in 2021. In the vast majority of countries demand for cough and cold products significantly decreased due to mask wearing control. In addition the focus in OTC and food supplements consumption is at vitamin D, immune supporting vitamins, and antivirals.

FINANCIAL RESULTS


Reported financial and alternative performance measure indicators represent main criteria used for information and performance analysis purposes and are presented or calculated based on the data disclosed in the Financial Statements and in the stock exchange www.nasdaqbaltic.com under ticker OLF1R. Neither the Parent Company or the Group has set the specific targets of the above indicators except for the Net revenue and the Net profit as the operating plan of the Parent Company and the Group for the reporting year. Information presented in this management report on sales by markets of the Group and sales by products of the Parent Company are direct components of the Net revenue providing additional dimension of the Net revenue for the performance of the reporting year as well as for the risk analysis purposes with comparative information described only in case of material changes.

Financial indicator for the period	01.01.2021 - 30.06.2021	% to prior period	01.01.2020 - 30.06.2020 (restated)	01.01.2019 - 30.06.2019 (restated)
Sales, EUR '000	66 671	100 %	66 369	66 392
Net Profit, EUR '000	7 668	77 %	10 017	12 244
EBITDA, EUR '000	12 129	68 %	17 924	15 123
EBIT, EUR '000	7 403	56 %	13 317	10 963
Gross margin	58.0 %		61.5%	61.9 %
EBITDA margin	18.2 %		27.0%	22.8 %
EBIT margin	11.1 %		20.1%	16.5 %
Net margin	11.5 %		15.1%	18.4 %
EPS, EUR	0.54	77 %	0.71	0.87
Financial indicator at the end of reporting period	30.06.2021	% to prior period	30.06.2020 (restated)	30.06.2019
Current ratio	3.0		3.6	1.9
Share price at period end, EUR	8.94	123 %	7.28	6.94
Market capitalization, EUR '000	125 921	123 %	102 539	97 750
P/B	0.9		0.7	0.8
Financial indicator for 12 months until the end of reporting date	01.07.2020 - 30.06.2021 (restated)	% to prior period	01.07.2019 - 30.06.2020 (restated)	01.07.2018 - 30.06.2019 (restated)
Sales, EUR '000	122 459	89 %	137 196	128 804
Net profit, EUR '000	7 129	36 %	20 036	17 189
EBITDA, EUR '000	19 066	58 %	32 760	25 614
DSCR	2.3		4.2	2.8
Net Debt-to-EBITDA	-0.54		-0.12	0.55
ROA	4.0 %		11.4 %	11.1 %
ROE	5.2 %		7.5 %	11.1 %
P/E	17.66		5.12	5.69

*Explanations of the formulas are given on page 16

Additional data for EBITDA calculation	01.01.2021 - 30.06.2021	% to prior period	01.01.2020 - 30.06.2020	01.01.2019 - 30.06.2019
Depreciation:	4 726	103 %	4 607	4 160
Intangible assets	446	122 %	367	339
Fixed assets	3 272	97 %	3 361	2 952
Rights-of-use assets	990	116 %	857	787
Investment properties	18	100 %	18	82
Value impairments:	-		4	-
Intangible assets	-		-	-
Fixed assets	-		4	-
Investment properties	-		-	-

During six months of 2021 the Group's sales reached EUR 66 671 thousand, which is close to same period of last year. Gross profit was EUR 38 662 thousand, which shows decrease by 2 188 thousand EUR or 5% compared to same time period last year. Gross profit margin in reporting period is 58.0 %, which is 3.5 p.p. drop compared to 61.5 % reached same period last year. Main impact on Gross profit changes comes from cost reclassification between administration expenses and manufacturing costs.



The Group's EBITDA figure for six months 2021 was EUR 12 129 thousand, which is 32 % or EUR 5 795 thousand EUR less than the result of the same period of 2020. EBITDA margin of the Group is 18.2 %.


In the last 12 months the Group's EBITDA was EUR 19 066 thousand and EBITDA margin was 16 %.

MARKETS

In 2021, the Group continued its ongoing activity in major markets. The highest sales in six months in 2021 was in Latvia, reaching 19 684 thousand EUR, which is 552 thousand EUR or 3% more than the same period year ago. Latvia sales represent 30% in Group revenues.

Sales in Russia for the six months period in 2021 amount to 18 092 thousand EUR which is decrease by 1 601 thousand EUR or 8% compared to the last year, however the last year ratio includes EUR 9 million unexpected deliveries to Russia in June 2020 due to the announced serialization. Group subsidiary in Russia is actively operating, proceeding with established robust digital communication channels, created patient support programs for anxiety discussions, and developed educational platform for healthcare professionals.

Sales results in Belarus result to 1 412 thousand EUR or 15% decrease against last year's results. The decline in demand in Belarus is closely linked to the political and economic crisis, the fall in the value of the Belarusian ruble against euro, as well as the application of a 10% value added tax on medicines starting in February 2021.




Group Net profit is EUR 7 668 thousand, which is a drop by EUR 2 349 thousand or 23% versus same period of previous year. Increase in selling expenses (+ EUR 2 449 thousand) is mainly related to active marketing campaigns of Group subsidiary in Russia and affiliate in Ukraine, which led to noticeable raise in net turnover in these markets. Other operating expenses (+ EUR 1 863 thousand) include provisions for bad-debts. The results in the reporting period were favorably affected by a positive difference from exchange rate fluctuations (Russian ruble against euro) on the contrary to significant losses during the first six months of the last year (total positive change in the finance income and expenses between current and previous year ratio is + EUR 3 584 thousand).

Performance in Ukraine is 1 229 thousand EUR or 24% increase compared to previous year with total sales 6 313 thousand EUR due to activation of affiliate’s marketing activities since Q4 2020.


Central Asia’ region shows 2 044 thousand EUR or 44% increase in sales compared to same period of the previous year, driven by increase of selling activities in Kazakhstan and Uzbekistan.

Group sales in major markets during six months of 2021 and the comparison with 2020 resulted in the following turnover breakdown:




PRODUCTS

In 2021, the Group continued the marketing and development of primary therapeutic area medicinal products. The most important therapeutic areas for the Group are medicine for health of nervous system, antibacterial medicine, medicine for cardiovascular health and anti-allergy medicine. Despite decline in all therapeutical categories across all markets, the top brands in neurology, cardiology, and anti-infectives outperform the market and gain market share in the relevant therapeutic categories.



The following chart shows JSC Olainfarm final dosage form sales of most demanded medicine in the six months period of 2021, compared to six months in 2020.



The most demanded products: Furamag/Furasol – antibacterial medicine, Neiromidin, Noofen, Adaptol - for health of nervous system, Etacizin – medicine for cardiovascular health, Fenkarol – anti-allergy medicine for children and adults.

In therapeutical areas the strongest decline in market consumption was observed in OTC categories. Despite weak OTC markets in the first half of 2021, Olainfarm products have shown stable demand due to brand recognition and renewed marketing strategy.

Neiromidin in Russia, Latvia, and Ukraine is growing faster than the relevant markets in Ukraine, Uzbekistan and Kazakhstan. Overall, CNS (central nervous system) franchise increased sales by 1 101 thousands EUR. Increased days of therapy in neuropathia and post-COVID astenia provided demand for these products. Furamag is ahead the last year by 220 thousand EUR driven by performance in Ukraine and Kazakhstan. Etacizin is above prior year by 600 thousand EUR with medical marketing support in Latvia, Russia, and Ukraine.

Sustainable demand for Fenkarol in Russia and Ukraine assured that despite declining markets across all countries, Fenkarol achieved the same result in the first half of 2021 as in the same period of the previous year.

RUSSIA MARKET IN THE FIRST HALF OF 2021

Group's sales in Russia in the first half of 2021 were lower than same ratio from the previous year, reaching EUR 18 092 thousand, which is a decrease of EUR 1 601 thousand.

Parent company's sales in Russia reached EUR 16 335 thousand, which is a decrease of EUR 2 075 thousand, however the last year's ratio includes EUR 9 million unexpected deliveries to Russia in June 2020 due to the announced serialization.

Group subsidiary in Russia is actively operating, proceeding with established robust digital communication channels, created patient support programs for anxiety discussions, and developed educational platform for healthcare professionals.

Olainfarm Parent company Sales in Russia, th EUR



The change in the value of the Russian ruble against the euro is 5%, from 91.5 per euro at the end of 2020 to 86.8 per euro at the end of Q2 2021.

JSC Olainfarm uses risk mitigation tools for transactions in Russian rubles.

EUR/RUB exchange rate



BUSINESS SEGMENTS

Group's companies manufacture a wide range of pharmaceutical and chemical products, food supplements, compression materials, cosmetic products, as well as provide medical services, offer retail of medicines in pharmacies as well as act as wholesalers for other manufacturers' medical products.

Main Group's segments operated with profit in the first six months of 2021. The largest profit before tax was generated by the medicine and chemical segment, which earned EUR 6 405 thousand, in wholesale the segment profit was EUR 690 thousand, retail (pharmacies) made EUR 297 thousand, and also in other segments the profit before tax reached EUR 86 thousand. The compression material segment generated a negative profit before tax of EUR 75 thousand.

Medicine production segment

The main business segment is Medicine production segment. Final dosage forms are manufactured by the Parent company in Olaine. In addition, the Parent company manufactures chemical components that are sold to other pharmaceutical companies covering a wide geographical area. In the first half of 2021, segment' sales worth EUR 42 951 thousand, which is 2 % or EUR 730 thousand increase if compared to the same time period of 2020 (mainly prescription products). This segment's share in the Group's total revenue in the reporting period reached 64 %, which is 1 % increase vs. prior year indicator.

Retail segment

Within the Group, SIA Latvijas Aptieka manages and develops pharmacies in Latvia where the Pharmacy segment in the first six months of 2021 show a revenue increase by 3 % compared to the same time period of 2020 and reached EUR 13 406 thousand. This segment's share in the Group's total revenue during the reporting period

INVESTMENTS AND DEVELOPMENT (R&D)

During the reporting period, investments were made in pre-clinical and clinical trials of medicines, including the implementation of the EU co-financed project "Pre-clinical and Clinical Trials of medicines". The planning of the clinical trial for the research project "Clinical trials for medicine registrations" was performed.

During the reporting period, investments were made in research of a synthetic route scouting and technology development for new active pharmaceutical ingredients. Research continues in the development of active pharmaceutical ingredients production technologies and in the development of new products - finished dosage forms, including the EU co-financed project "Active Pharmaceutical Ingredients Research".

In the first half of 2021, the planning of four Phase 3 clinical trials was performed and the necessary actions for the

initiation of trials, which were planned to be started in 2021, in accordance with the limitations and risks related to the implementation of the Covid-19 pandemic.

Compression materials

Group's company SIA Tonus Elast manufactures a wide range of compression materials and sells products in Latvia and abroad. Revenue of this segment in the first six months of 2021 was EUR 3 931 thousand that is an increase by 34 % than the year before. This segment's share in the Group's total revenue in the reporting period was 6 % (+2 p.p). SIA Tonus Elast has won the first place as the best European brand in compression and orthopedics product segment at annual "SmartPharma awards 2021", which took place in April 2021 in Moscow.

Wholesale

Within the Group, the Parent company manages the wholesale of medical products since it has a medicine wholesale license, which allows to purchase products from other manufacturers and to deliver them to SIA Latvijas aptieka as well as other cooperation partners. Revenue of this segment in six months of 2021 was EUR 1 736 thousand, which is 46 % decrease compared to last year ratio.

Other

This segment combines SIA Silvanols, SIA DiaMed and SIA OlainMed medical facilities, the Belarussian manufacturing company NPK Biotest and others which generated EUR 4 647 thousand in revenue in six months of 2021 and is 7 % less than in the same period of 2020. This segment's share in the Group's total revenue during the reporting period was 7 % (-1 pp).



In the 2nd quarter of 2021 enrollment of volunteers has started in Phase 3 clinical trial for the treatment of diseases of the peripheral nervous system.

The investments made are fully financed from the Group's cash flow.

JSC Olainfarm and Adalvo have signed a licensing and supply agreement to launch a new urology product in 17 countries in 2022 - 2023. Adalvo, a part of Alvogen Group,

is one of the leading B2B pharmaceutical companies in Europe.

During the reporting period the investments mainly made in production, product development, IT and digitalization. Covid-19 pandemic restrictions and economic consequences significantly influenced the possibilities of the Group to realize planned investments.

FINANCIAL AND LIQUIDITY MANAGEMENT

The Group's financial position during the first half of 2021 is stable. The Group's successful operations allowed it to accumulate EUR 25 881 thousand in cash at the end of June 2021. This is a significant precondition to limit the effect of uncertainty within the sales markets as well as allows to safeguard supply of raw materials in order to maintain stable operations. Accumulated cash allows to use less of external financing, reducing the group's financial costs.

With the aim to improving the efficiency of the Company's financial risk management, a "Financial Risk Management

Policy" has been introduced at JSC "Olainfarm". Due to one of the company's major markets is Russia and trade with this market is operated in local currency, the Company continued to use risk mitigation tools.

The Group's Debt service coverage ratio (DSCR) in six months of 2021 was 2.6. Net Debt-to-EBITDA ratio was negative -0.9 explained that cash balance exceeds net debt.

SOCIAL RESPONSIBILITY

On the safety and health of employees during THE COVID - 19 pandemic, AS Olainfarm provides a series of precautions to reduce the risk of infections and the spread of the virus in the workplace.

SIA "Klīnika DiaMed" and SIA "Olainmed" have engaged in vaccination of Latvian residents against Covid-19, setting up vaccination points in Riga and Olaine.

The mission of JSC "Olainfarm" Group is to improve human health and quality of life, therefore from March to May 2021 the company created a four series "Olainfarm Mental Health Talks". In these online events, which were available on the portal Delfi.lv and on the Facebook company profile (<https://www.facebook.com/JSCOlainFarm>), experts in Latvia - doctors, psychotherapists and neurologists spoke about various aspects of psycho-emotional health, providing extensive information on mental health preservation,

maintenance, symptoms suggestive of burnout or other problems and provided advice on how to deal with these issues. As part of a series of conversations, the experts answered the audience's questions and provided practical recommendations for promoting emotional well-being. Program recordings are still available to everyone on the Facebook profile of JSC Olainfarm.

With the support of JSC "Olainfarm", the television broadcast "Two knows better" was created, which was broadcast on "TV 24 Rīga". Between 24 March and the end of May 2021, in thirteen series of the broadcast, experts and industry experts explained various health-related issues, such as immunity, nervous system, colds, allergies, cardiovascular disease, or vegetative dystonia. To ensure the widest possible availability of information, the topics of the program were also presented on the Facebook page of JSC Olainfarm.

CORPORATE GOVERNANCE

On 17 June 2021 Extraordinary General Meeting of Shareholders approved new wording for the Remuneration Policy for Council and Management board.

EVENTS AFTER REPORTING DATE

According to the decision taken at Meeting of Shareholders on 18 June 2021, JSC "Olainfarm" has paid dividend EUR 2 394 thousand (0.17 EUR per share) on 12 July 2021.

On July 30, the Supervisory Council of JSC Olainfarm has elected Jānis Buks as the Chairperson of the Management Board.

According to 14 July 2021 Financial Capital Market Commission decision and the official announcement of the publisher "Latvijas Vestnesis" on 16 July 2021, on 19 July 2021 JSC AB CITY (the Offeror) began the mandatory share repurchase offer process. On

17 August share repurchase offer process ended and according to the report submitted by JSC AB CITY during the time period of the offer 2 427 408 shares of the Company were offered for sale. After implementation of the share buy-back offer in the disposal of the Offeror would be 2 427 408 shares or 17.23% from the total number of voting rights of the Company owned by the Offeror and indirectly acquired voting rights arising from the shares of the Company which constitute 30,85 % from the total number of voting rights of the Company, which in total constitutes 48.08% from the total number of voting rights of the Company.

Since the end of the reporting period until the approval date of these financial statements there have been no other significant events with effect on the financial position or financial results of the Group as at the balance sheet date.

On behalf of the Management Board of JSC Olainfarm:

(signature)
Jānis Buks
Chairman of the Management Board

(signature)
Jānis Leimanis
Member of the Management Board

August 27, 2021

DEFINITIONS

DSCR – EBITDA / Debt payments (Including Interest)

EBIT - Earnings before taxes and finance income, finance expense for the reporting period

EBITDA - Earnings before taxes and finance income, finance expense, depreciation and amortization, including impairment of non-financial assets, for the reporting period

FDA – US Food and Drug Administration standards

OTC – Over-the-counter drugs

P/E – Share Price / Net earnings per share

ROA – Net Profit / (Net assets at the beginning of the reporting period + Net assets at the end of the reporting period) / 2

ROE – Net Profit / (Equity value at the beginning of the reporting period + Equity value at the end of the reporting period) / 2

TGA – Australian Therapeutic Goods Administration standards

EBITDA margin – EBITDA / Net turnover

EBIT margin – EBIT / Net turnover

Net margin – Net earnings / Net turnover

EPS – Net earnings / End of period shares outstanding

Current ratio – Current Assets / Current Liabilities

Net Debt-to-EBITDA - (Short-term debt + Long-term debt – Cash and cash equivalents) / EBITDA

Statement of responsibility of the management

The Management Board of JSC Olainfarm prepares interim condensed consolidated financial statements for each quarter which give a true and fair view of the JSC Olainfarm group's (hereinafter - the Group) assets, liabilities and financial position as of the end of the respective interim period, and the financial results of the Group for that respective period. Interim condensed consolidated financial statements are prepared based on International Financial Reporting Standards as adopted by the EU in respect of interim financial statements. In preparing those financial statements, management:

- selects suitable accounting policies and then apply them consistently;
- makes judgments and estimates that are reasonable and prudent;
- prepares the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Management Board of JSC Olainfarm is responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position, financial performance and cash flows of the Parent Company and the Group and enable them to ensure that financial statements drawn up from them comply with International Financial Reporting Standards as adopted by the EU.

On behalf of the Management Board of JSC Olainfarm:

(signature)
Jānis Buks
Chairman of the Management Board

(signature)
Jānis Leimanis
Member of the Management Board

August 27, 2021

INTERIM CONSOLIDATED FINANCIAL STATEMENTS**Interim consolidated statement of comprehensive income**

	01.01.2021 - 30.06.2021	01.01.2020 - 30.06.2020
	EUR '000	EUR '000
Revenue	66 671	66 369
Cost of goods sold	(28 009)	(25 519)
Gross profit	38 662	40 850
Selling expenses	(15 117)	(12 668)
Administrative expenses	(15 046)	(15 240)
Other operating income	1 485	1 075
Other operating expenses	(2 578)	(715)
Share of (loss) / profit of an associate	(3)	15
Finance income	734	38
Finance expense	(306)	(3 194)
Profit before tax	7 831	10 161
Corporate income tax	(184)	(158)
Deferred corporate income tax	21	14
Profit for the reporting period	7 668	10 017
Other comprehensive income for the reporting period		
<i>Other comprehensive income to be reclassified to profit or loss in subsequent periods, net of tax:</i>		
Exchange differences on translation of foreign operations	120	(328)
Other comprehensive income / (loss) for the reporting period, net of tax	120	(328)
Total comprehensive income for the reporting period, net of tax	7 788	9 689
Profit attributable to:		
The equity holders of the Parent company	7 668	10 017
Non-controlling interests	-	-
	7 668	10 017
Total comprehensive income attributable to:		
The equity holders of the Parent company	7 788	9 689
Non-controlling interests	-	-
	7 788	9 689
Basic and diluted earnings per share, EUR	0.54	0.71

The accompanying notes form an integral part of these financial statements.

On behalf of the Management Board of JSC Olainfarm:

(signature)

Jānis Buks
Chairman of the Management Board

(signature)

Jānis Leimanis
Member of the Management Board

August 27, 2021

Interim consolidated statement of financial position

ASSETS	30.06.2021	31.12.2020	31.12.2019
		(restated)	(restated)
	EUR '000	EUR '000	EUR '000
NON-CURRENT ASSETS			
Intangible assets	42 459	40 843	38 414
Property, plant and equipment	41 047	40 994	41 989
Right-of-use assets	8 016	7 198	7 069
Investment property	199	217	253
Other long-term investments			
Investments in associated companies	399	402	504
Loans to management, employees and shareholders	195	210	203
Other non-current assets	1	1	11
Deferred corporate income tax assets	130	104	64
TOTAL	725	717	782
TOTAL NON-CURRENT ASSETS	92 446	89 969	88 507
CURRENT ASSETS			
Inventories			
Raw materials	6 212	5 569	5 209
Work in progress	14 994	15 013	12 298
Finished goods and goods for sale	14 678	13 209	13 429
Prepayments for goods	285	659	658
TOTAL	36 169	34 450	31 594
Receivables and other current assets			
Trade receivables	22 116	20 572	31 280
Other current assets	1 391	930	1 383
Other receivables	4 224	1 751	975
Corporate income tax	47	721	919
Loans to management, employees and shareholders	1 718	1 688	1 610
Contract assets	824	655	519
TOTAL	30 320	26 317	36 686
Cash	25 881	24 451	15 230
TOTAL CURRENT ASSETS	92 370	85 218	83 510
TOTAL ASSETS	184 816	175 187	172 017

The accompanying notes form an integral part of these financial statements.

On behalf of the Management Board of JSC Olainfarm:

(signature)

Jānis Buks
Chairman of the Management Board

(signature)

Jānis Leimanis
Member of the Management Board

August 27, 2021

Interim consolidated statement of financial position

EQUITY AND LIABILITIES		30.06.2021	31.12.2020	31.12.2019
			(restated)	(restated)
EQUITY		EUR '000	EUR '000	EUR '000
Share capital		19 719	19 719	19 719
Share premium		2 504	2 504	2 504
Reserves		(592)	(712)	(12)
Retained earnings:				
brought forward		110 035	102 951	85 017
for the period		7 668	9 478	22 263
	TOTAL EQUITY	139 334	133 940	129 491
LIABILITIES				
Non-current liabilities				
Loans from credit institutions		5 255	6 401	7 004
Lease liabilities		5 835	5 359	5 173
Deferred income		3 912	3 923	3 194
Taxes payable		43	25	-
	TOTAL	15 045	15 708	15 371
Current liabilities				
Loans from credit institutions		2 357	4 630	6 723
Lease liabilities		2 123	1 766	1 763
Other loans		-	-	1 082
Trade payables		11 167	10 248	9 896
Contract liabilities		514	730	479
Dividends payable		2 394	-	-
Taxes payable		2 127	1 122	1 504
Deferred income		518	529	495
Accrued liabilities		9 237	6 514	5 213
	TOTAL	30 437	25 539	27 155
	TOTAL LIABILITIES	45 482	41 247	42 526
TOTAL EQUITY AND LIABILITIES		184 816	175 187	172 017

The accompanying notes form an integral part of these financial statements.

On behalf of the Management Board of JSC Olainfarm:

(signature)
Jānis Buks
Chairman of the Management Board

(signature)
Jānis Leimanis
Member of the Management Board

August 27, 2021

Interim consolidated statement of cash flow

	01.01.2021 - 30.06.2021	01.01.2020 - 30.06.2020
	EUR '000	EUR '000
Cash flows from operating activities		
Profit before taxes	7 831	10 161
Adjustments for:		
Amortization and depreciation	4 726	4 603
Net (profit)/ loss on sale/ disposal of non-current assets	(52)	239
Increase in provisions and accrued liabilities	3 519	1 715
Share of loss/ (profit) of an associate	3	(15)
Interest expenses	306	355
Interest income	(41)	(35)
Income from EU projects funds	(308)	(316)
Unrealised (profit)/ loss from fluctuations of currency exchange rates	(625)	100
Operating cash flows before changes in working capital	15 359	16 807
Increase in inventories	(1 337)	(2 401)
(Increase)/ decrease in receivables and prepaid expenses	(3 666)	1 434
Decrease in payables and prepayments received	(512)	(1 021)
Cash generated from operating activities	9 844	14 819
Corporate income tax paid	(227)	(132)
Net cash flows from operating activities	9 617	14 687
Cash flows from investing activities		
Purchase of intangible assets and property, plant and equipment	(4 591)	(4 370)
Receipt of EU grants	211	874
Dividends received	-	80
Proceeds from sale of intangible assets and property, plant and equipment	475	79
Repayment of loans granted	12	10
Interest received	8	-
Loans granted	(19)	(30)
Net cash used in investing activities	(3 904)	(3 357)
Cash flows from financing activities		
Repayment of loans	(3 419)	(3 462)
Lease payments	(961)	(849)
Interest paid	(306)	(341)
Proceeds from loans	-	1 867
Net cash used in financing activities	(4 686)	(2 785)
Net change in cash	1 027	8 545
Effect of movements in exchange rates	403	(22)
Cash at the beginning of the year	24 451	15 230
Cash at the end of the reporting period	25 881	23 753

The accompanying notes form an integral part of these financial statements.

Interim consolidated statement of changes in equity

	Equity attributable to the equity holders of the Parent company					
	Share capital	Share premium	Reserves	Foreign currency translation reserve	Retained earnings	Total
	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000
Balance as at 31 December 2019	19 719	2 504	40	(52)	103 933	126 144
Change of method for measuring inventory costs	-	-	-	-	3 347	3 347
Balance as at 31 December 2019 (restated)	19 719	2 504	40	(52)	107 280	129 491
Profit for the reporting period	-	-	-	-	10 017	10 017
Other comprehensive income	-	-	-	(328)	-	(328)
Total comprehensive income	-	-	-	(328)	10 017	9 689
Change of method for measuring inventory costs	-	-	-	-	627	627
Balance as at 30 June 2020 (restated)	19 719	2 504	40	(380)	117 924	139 807
Balance as at 31 December 2020	19 719	2 504	40	(752)	108 904	130 415
Change of method for measuring inventory costs	-	-	-	-	3 525	3 525
Balance as at 31 December 2020 (restated)	19 719	2 504	40	(752)	112 429	133 940
Profit for the reporting period	-	-	-	-	7 668	7 668
Other comprehensive income	-	-	-	120	-	120
Total comprehensive income	-	-	-	120	7 668	7 788
Dividends	-	-	-	-	(2 394)	(2 394)
Balance as at 30 June 2021	19 719	2 504	40	(632)	117 703	139 334

The accompanying notes form an integral part of these financial statements

Notes to the interim condensed consolidated financial statements**1. Corporate information**

The principal activities of Olainfarm Group (hereinafter, the Group) are manufacturing and distribution of chemical and pharmaceutical products. The Parent Company of the Group, JSC Olainfarm (hereinafter, the Parent Company) was registered with the Republic of Latvia Enterprise Register on 10 June 1991 (re-registered on 27 March 1997) and with the Republic of Latvia Commercial Register on 4 August 2004. The shares of the Parent Company are listed on Nasdaq Riga, Latvia.

These unaudited interim condensed consolidated financial statements (hereinafter – the interim financial statements) were approved by the Management Board on 27 August 2021.

2. Basis of preparation and changes to the Group's accounting policies***Basis of preparation***

The interim condensed consolidated financial statements for six months ending on 30 June 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual financial statements as of 31 December 2020.

The interim financial statements are presented in euro (EUR), the monetary unit of the Republic of Latvia, and rounded to the nearest thousand (EUR '000 or thsd. EUR).

The interim financial statements comprise the financial statements of the Parent Company and all its subsidiaries as of 30 June 2021.

Changes in accounting policy and disclosures

The accounting policies are consistent with those followed in the preparation of the Group's annual financial statements for the year ending on 31 December 2020. The Group has evaluated new and amended IFRSs and IFRICs effective for annual periods beginning on or after 1 January 2021. No impact on the interim financial statements of the Group was identified.

The Group has not applied early the IFRS and IFRIC interpretations that have been issued as of the date of authorization of these financial statements for issue, but which are not yet effective. The Group plans to adopt these standards and interpretations on their effectiveness dates provided they are endorsed by the EU.

Change of method for measuring inventory costs

To ensure the most appropriate measuring of inventory costs in the year 2021 JSC Olainfarm changed its accounting policy: for measurement of finished goods is used the standard cost method. The method of measurement of the costs for all other inventories has been changed from weighted average cost method to FIFO (first-in, first-out). The accounting policy change has been applied retrospectively by adjusting each affected financial statements line item as if the new accounting policy had always been applied. The effect of changes is shown below:

Statement of financial position

	31.12.2019 before restatement	Restatement	31.12.2019 after restatement
	EUR '000	EUR '000	EUR '000
<i>Assets</i>			
Work in progress	10 170	2 128	12 298
Finished goods and goods for sale	12 210	1 219	13 429
<i>Equity and liabilities</i>			
Retained earnings for previous years	81 670	3 347	85 017

	31.12.2020 before restatement	Restatement	31.12.2020 after restatement
	EUR '000	EUR '000	EUR '000
Assets			
Work in progress	12 632	2 381	15 013
Finished goods and goods for sale	12 065	1 144	13 209
Equity and liabilities			
Retained earnings for previous years	99 426	3 525	102 951

Statement of changes in equity

	31.12.2019 before restatement	Restatement	31.12.2019 after restatement
	EUR '000	EUR '000	EUR '000
Retained earnings	103 933	3 347	107 280

	31.12.2020 before restatement	Restatement	31.12.2020 after restatement
	EUR '000	EUR '000	EUR '000
Retained earnings	108 904	3 525	112 429

3. Revenue

Note discloses revenue from agreements with customers.

	01.01.2021 - 30.06.2021	01.01.2020 - 30.06.2020
	EUR '000	EUR '000
By business segments		
Finished form medicine	39 140	39 426
Pharmacies	13 406	13 019
Compression materials	3 931	2 939
Wholesale	1 736	3 213
Chemicals	3 811	2 795
Other	4 647	4 977
TOTAL:	66 671	66 369

	01.01.2021 - 30.06.2021	01.01.2020 - 30.06.2020
	EUR '000	EUR '000
By geographical markets		
Russia	18 092	19 693
Latvia	19 684	19 132
Belarus	7 734	9 146
Ukraine	6 313	5 084
Central Asia	6 723	4 679
EU countries	4 803	5 067
Other countries	1 702	2 345
Caucasus countries	1 620	1 223
TOTAL:	66 671	66 369

	01.01.2021 - 30.06.2021	01.01.2020 - 30.06.2020
	EUR '000	EUR '000
Timing of revenue recognition		
At a point in time:		
Sale of goods	64 792	65 043
Rendering of services	1 879	1 326
TOTAL:	66 671	66 369

4. Property, plant and equipment

During the reporting period the investments of EUR 175 thsd. were provided by the EU co-financed project "Reduction of Greenhouse Gas Emissions by Reconstruction JSC Olainfarm Refrigeration station and its Engineering System". Within the project, reconstruction works of production workshop No. 6, delivery and installation of technological equipment of the refrigeration system, and reconstruction works of the external cooling network were performed. Project implementation completed by 28 February 2021.

During the reporting period the investments of EUR 1 374 thsd. were provided for pre-clinical and clinical trials, including EUR 299 thsd. provided under the EU co-financed project "Pre-clinical and clinical trials". The investments made are fully financed from cash flows of the company.

5. Loans from credit institutions

During the reporting period AS SEB banka loan in the amount of EUR 2 354 thsd. was fully repaid. JSC Olainfarm loan liabilities to the financial partner AS SEB banka as of 30 June 2021 consisted of the unused credit line with assigned limit of EUR 1 000 thsd. The term of the Loan agreement is 30 June 2021.

JSC Olainfarm loan liabilities to the financial partner JSC BlueOrange Bank as of 30 June 2021 consist of the loan in the amount of EUR 7 271 thsd. and the term of the Loan agreement is 20 August 2024.

6. Related party disclosures

Related party	Type of services		Goods and services	Goods, services and	Amounts	Amounts
			delivered to/ Loans issued to related parties	loans received from related parties	owed by related parties (gross)	owed to related parties (gross)
			EUR '000	EUR '000	EUR '000	EUR '000
1. Associated entities						
SIA Olainfarm enerģija (AS Olainfarm share 50%)	Energy production and other services	31.12.2020	35	303	3	-
		30.06.2021	236	174	3	19
		TOTAL: 31.12.2020	35	303	3	-
		TOTAL: 30.06.2021	236	174	3	19
2. Parties with significant influence						
SIA Olmafarm (shareholder)	Loan	31.12.2020	-	10	-	-
		30.06.2021	-	-	-	-
Heirs of V. Maligins	Loan and travelling services	31.12.2020	67	34	2 078	35
		30.06.2021	33	-	2 111	35
		TOTAL: 31.12.2020	67	44	2 078	35
		TOTAL: 30.06.2021	33	-	2 111	35
3. Other Related companies						
SIA Vega MS (Heirs of V. Maligins share 59.99%)	Security and other services	31.12.2020	-	26	-	-
		30.06.2021	-	4	-	-
SIA Lano Serviss (Heirs of V. Maligins share 25%)	Dry cleaning and other services	31.12.2020	8	21	-	-
		30.06.2021	-	-	-	-
SIA Olfa Press (Heirs of V. Maligins share 47.5%)	Printing and other services	31.12.2020	51	1 371	4	182
		30.06.2021	25	818	4	213
		TOTAL: 31.12.2020	59	1 418	4	182
		TOTAL: 30.06.2021	25	822	4	213

7. Segment information

	Medicine Production	Wholesale	Retail	Compression Materials	Other segments	Total segments	Unallocated and eliminated	Consolidated
	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000	EUR '000
Revenue								
External customers								
6M 2021	42 951	1 736	13 406	3 931	4 647	66 671	-	66 671
6M 2020	42 221	3 213	13 019	2 939	4 977	66 369	-	66 369
Inter-segment								
6M 2021	502	6 460	184	1 806	117	9 069	(9 069)	-
6M 2020	462	5 921	204	622	534	7 743	(7 743)	-
Total revenue								
6M 2021	43 453	8 196	13 590	5 737	4 764	75 740	(9 069)	66 671
6M 2020	42 683	9 134	13 223	3 561	5 511	74 112	(7 743)	66 369
Segment profit before tax								
6M 2021	6 405	690	297	(75)	86	7 403	428	7 831
6M 2020	11 935	1 371	303	20	(312)	13 317	(3 156)	10 161
Assets								
30.06.2021	101 595	5 728	32 427	17 229	12 336	169 315	15 501	184 816
31.12.2020	92 841	6 079	32 379	16 251	11 578	159 128	16 059	175 187
Liabilities								
30.06.2021	26 403	3 837	8 458	3 240	6 838	48 776	(3 294)	45 482
31.12.2020	20 353	3 677	8 597	2 517	6 885	42 029	(782)	41 247
Capital expenditure								
6M 2021	5 357	4	72	210	129	5 772	-	5 772
6M 2020	5 070	-	51	49	96	5 266	-	5 266

Segments financial data, excluding Segment profit before tax, presented without elimination of intercompany transaction impact.

There was made reclassification from the position Unallocated and eliminated to all segments positions and accordingly were reclassified the data of the year 2020.

Reconciliation of profit	6M 2021	6M 2020
	EUR '000	EUR '000
Segment profit before tax	7 403	13 317
Unallocated financial income	734	38
Unallocated financial expenses	(306)	(3 194)
Profit before tax	7 831	10 161
Reconciliation of assets	30.06.2021	31.12.2020
	EUR '000	EUR '000
Assets of segments in total	169 315	159 128
Unallocated long term assets and eliminations	1 544	2 281
Unallocated short term assets and eliminations	(8 774)	(7 905)
Cash managed on group level	22 731	21 683
Total assets	184 816	175 187
Reconciliation of Liabilities	30.06.2021	31.12.2020
	EUR '000	EUR '000
Liabilities of segments in total	48 776	42 029
Interest bearing loans and borrowings	7 302	10 683
Current tax liabilities	-	(24)
Other unallocated liabilities and eliminations	(10 596)	(11 441)
Total liabilities	45 482	41 247

8. Dividends

On June 18, 2021 the General Meeting of Shareholders of JSC Olainfarm decided to pay dividends to shareholders in amount of EUR 2 394 thsd. (EUR 0.17 per share) from prior year's profit, which is stated on the balance sheet as at 31 December 2017, arranging dividends payout in the third quarter 2021. Dividends payout was processed on July 12, 2021.

9. Events after the reporting period

Details of the events after the end of the reporting period are described in the Management report accompanying these interim financial statements. Since the end of the reporting period until the approval date of these financial statements there have been no other significant events with effect on the financial position or financial results of the Group as of the balance sheet date.